These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

72 related articles for article (PubMed ID: 22552265)

  • 21. Effects of age and sex on the single-dose pharmacokinetics and pharmacodynamics of apixaban.
    Frost CE; Song Y; Shenker A; Wang J; Barrett YC; Schuster A; Harris SI; LaCreta F
    Clin Pharmacokinet; 2015 Jun; 54(6):651-62. PubMed ID: 25573421
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effect of multiple doses of omeprazole on the pharmacokinetics, pharmacodynamics, and safety of a single dose of rivaroxaban.
    Moore KT; Plotnikov AN; Thyssen A; Vaccaro N; Ariyawansa J; Burton PB
    J Cardiovasc Pharmacol; 2011 Dec; 58(6):581-8. PubMed ID: 21822144
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pharmacokinetics and pharmacodynamics of AR9281, an inhibitor of soluble epoxide hydrolase, in single- and multiple-dose studies in healthy human subjects.
    Chen D; Whitcomb R; MacIntyre E; Tran V; Do ZN; Sabry J; Patel DV; Anandan SK; Gless R; Webb HK
    J Clin Pharmacol; 2012 Mar; 52(3):319-28. PubMed ID: 21422238
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pharmacokinetics, pharmacodynamics, and tolerance of single- and multiple-dose fexofenadine hydrochloride in healthy male volunteers.
    Russell T; Stoltz M; Weir S
    Clin Pharmacol Ther; 1998 Dec; 64(6):612-21. PubMed ID: 9871426
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Multiple-dose pharmacokinetics, pharmacodynamics, and safety of atorvastatin, an inhibitor of HMG-CoA reductase, in healthy subjects.
    Cilla DD; Whitfield LR; Gibson DM; Sedman AJ; Posvar EL
    Clin Pharmacol Ther; 1996 Dec; 60(6):687-95. PubMed ID: 8988072
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pharmacokinetics and pharmacodynamics of sitagliptin, an inhibitor of dipeptidyl peptidase IV, in healthy subjects: results from two randomized, double-blind, placebo-controlled studies with single oral doses.
    Herman GA; Stevens C; Van Dyck K; Bergman A; Yi B; De Smet M; Snyder K; Hilliard D; Tanen M; Tanaka W; Wang AQ; Zeng W; Musson D; Winchell G; Davies MJ; Ramael S; Gottesdiener KM; Wagner JA
    Clin Pharmacol Ther; 2005 Dec; 78(6):675-88. PubMed ID: 16338283
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pharmacokinetic and pharmacodynamic assessments of the dipeptidyl peptidase-4 inhibitor PHX1149: double-blind, placebo-controlled, single- and multiple-dose studies in healthy subjects.
    O'Farrell AM; van Vliet A; Abou Farha K; Cherrington JM; Campbell DA; Li X; Hanway D; Li J; Guler HP
    Clin Ther; 2007 Aug; 29(8):1692-705. PubMed ID: 17919550
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Phase I study of Solulin, a novel recombinant soluble human thrombomodulin analogue.
    van Iersel T; Stroissnig H; Giesen P; Wemer J; Wilhelm-Ogunbiyi K
    Thromb Haemost; 2011 Feb; 105(2):302-12. PubMed ID: 21103657
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effects of the oral, direct factor xa inhibitor rivaroxaban on platelet-induced thrombin generation and prothrombinase activity.
    Graff J; von Hentig N; Misselwitz F; Kubitza D; Becka M; Breddin HK; Harder S
    J Clin Pharmacol; 2007 Nov; 47(11):1398-407. PubMed ID: 17873238
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Clinical safety, tolerability, pharmacokinetics and pharmacodynamics of the novel factor Xa inhibitor DY-807f in healthy volunteers.
    Ogata K; Shimizu T; Masumoto H; Oguma T; Sugiyama N; Kunitada S
    Thromb Res; 2015 Apr; 135(4):594-601. PubMed ID: 25700621
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Assessment of laboratory assays to measure rivaroxaban--an oral, direct factor Xa inhibitor.
    Samama MM; Martinoli JL; LeFlem L; Guinet C; Plu-Bureau G; Depasse F; Perzborn E
    Thromb Haemost; 2010 Apr; 103(4):815-25. PubMed ID: 20135059
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pharmacokinetics, pharmacodynamics, and tolerability of single increasing doses of the dipeptidyl peptidase-4 inhibitor alogliptin in healthy male subjects.
    Christopher R; Covington P; Davenport M; Fleck P; Mekki QA; Wann ER; Karim A
    Clin Ther; 2008 Mar; 30(3):513-27. PubMed ID: 18405789
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pharmacokinetics, safety and tolerability of intravenous ferric carboxymaltose: a dose-escalation study in volunteers with mild iron-deficiency anaemia.
    Geisser P; Banké-Bochita J
    Arzneimittelforschung; 2010; 60(6a):362-72. PubMed ID: 20648928
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Direct and rapid inhibition of factor Xa by otamixaban: a pharmacokinetic and pharmacodynamic investigation in patients with coronary artery disease.
    Hinder M; Frick A; Jordaan P; Hesse G; Gebauer A; Maas J; Paccaly A
    Clin Pharmacol Ther; 2006 Dec; 80(6):691-702. PubMed ID: 17178269
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Entecavir pharmacokinetics, safety, and tolerability after multiple ascending doses in healthy subjects.
    Yan JH; Bifano M; Olsen S; Smith RA; Zhang D; Grasela DM; LaCreta F
    J Clin Pharmacol; 2006 Nov; 46(11):1250-8. PubMed ID: 17050790
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Xa inhibition and coagulation activity--the influence of prolonged dalteparin treatment and gender in patients with acute coronary syndrome and healthy individuals.
    Oldgren J; Johnston N; Siegbahn A
    Am Heart J; 2008 Mar; 155(3):493.e1-8. PubMed ID: 18294482
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Safety, tolerability, and pharmacokinetics of eliglustat tartrate (Genz-112638) after single doses, multiple doses, and food in healthy volunteers.
    Peterschmitt MJ; Burke A; Blankstein L; Smith SE; Puga AC; Kramer WG; Harris JA; Mathews D; Bonate PL
    J Clin Pharmacol; 2011 May; 51(5):695-705. PubMed ID: 20864621
    [TBL] [Abstract][Full Text] [Related]  

  • 38. First-in-Human Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of an Oral Formulation of DS-1040, an Inhibitor of the Activated Form of Thrombin-Activatable Fibrinolysis Inhibitor, in Healthy Subjects.
    Zhou J; Limsakun T; Yin O; Warren V; Zamora C; Atiee G; Kochan J; Pav J; Kobayashi F; Vashi V; Dishy V
    J Clin Pharmacol; 2019 Dec; 59(12):1669-1677. PubMed ID: 31243790
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pharmacokinetics and pharmacodynamics of BIBT 986, a novel small molecule dual inhibitor of thrombin and factor Xa.
    Graefe-Mody EU; Schühly U; Rathgen K; Stähle H; Leitner JM; Jilma B
    J Thromb Haemost; 2006 Jul; 4(7):1502-9. PubMed ID: 16839346
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Safety, Pharmacokinetics, and Pharmacodynamics in Healthy Volunteers Treated With GDC-0853, a Selective Reversible Bruton's Tyrosine Kinase Inhibitor.
    Herman AE; Chinn LW; Kotwal SG; Murray ER; Zhao R; Florero M; Lin A; Moein A; Wang R; Bremer M; Kokubu S; Serone AP; Hanze EL; Viberg A; Morimoto AM; Winter HR; Katsumoto TR
    Clin Pharmacol Ther; 2018 Jun; 103(6):1020-1028. PubMed ID: 29484638
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.